Skip to main content
BYSI
NASDAQ Life Sciences

BeyondSpring Receives Nasdaq Delisting Notice After 30 Days Below $1.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.75
Mkt Cap
$30.832M
52W Low
$0.566
52W High
$2.44
52W Position info
33% above low
Off High info
69% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BYSI sits 33% above its 52-week low of $0.566 on light trading volume (0.1× avg).

Summary

BeyondSpring received a Nasdaq delisting notice on September 17, 2026, after its stock traded below $1.00 for 30 consecutive business days. The company has until March 16, 2027, to regain compliance.


Key Events · Legal and Risk Events · BYSI

  • Nasdaq Delisting Notice Received

    On September 17, 2026, Nasdaq notified BeyondSpring that its ordinary shares failed the $1.00 minimum bid price requirement for 30 consecutive business days under Listing Rule 5550(a)(2).

  • 180-Day Compliance Period

    The company has until March 16, 2027, to regain compliance by closing at or above $1.00 per share for at least ten consecutive business days.

  • Possible Additional Grace Period

    If compliance is not regained by March 16, 2027, the company may be eligible for an additional 180-day compliance period, subject to Nasdaq staff determination.

  • Compounding Distress

    The delisting notice follows the company's August 2026 10-Q, which disclosed going concern doubt and the termination of its Eli Lilly collaboration.


Analysis · BYSI · Life Sciences

BeyondSpring has been formally notified by Nasdaq that its ordinary shares no longer meet the $1.00 minimum bid price requirement, having traded below that threshold for 30 consecutive business days. The company now has 180 calendar days — until March 16, 2027 — to regain compliance by closing at or above $1.00 for at least ten consecutive business days. This comes against a backdrop of already severe distress: the company's most recent 10-Q disclosed going concern doubt and the termination of its Eli Lilly collaboration. A delisting notice materially raises the risk that the company loses its Nasdaq listing entirely, which would further impair liquidity and access to capital at a time when the company is already fighting for survival.

How filings like this one have moved

In the 30 days to Sep 18, 2026, 40.1% of the 362 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BYSI was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.8M. The 52-week trading range was $0.57 to $2.44. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BYSI - Latest Insights

BYSI
Aug 14, 2026, 5:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.821
Real-time Price: $0.7498 info
Change: -$0.0712 (-9%) info
Market Cap: $30.832M info
BYSI
Aug 14, 2026, 5:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.821
Real-time Price: $0.7498 info
Change: -$0.0712 (-9%) info
Market Cap: $30.832M info
BYSI
Jun 29, 2026, 4:30 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $0.7498 info
Change: -$1.04 (-58%) info
Market Cap: $30.832M info
BYSI
Jun 04, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $0.7498 info
Change: -$0.9902 (-57%) info
Market Cap: $30.832M info
BYSI
Jun 04, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $0.7498 info
Change: -$0.9902 (-57%) info
Market Cap: $30.832M info